The study population includes up to 110 adult male and female participants ages 18-55 years. Participants may have multiple food allergies but must be peanut allergic in order to be included. Safety assessments will include the following: physical examination, vital signs, laboratory evaluations, and ECG (electrocardiogram).
The purpose of this study is to learn which treatment works best in patients with pancreatic cancer. The study explores multiple treatment combinations. A study drug called atezolizumab may be combined with other drugs such as cobimetinib, PEGPH20, and BL-8040. Patients may also be assigned to receive standard chemotherapy treatment.